HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study. - Wikidata - wikimedia - TriplyDB

HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study.

HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study.

http://www.wikidata.org/entity/Q33274430

about

Epigenetic regulation in estrogen receptor positive breast cancer--role in treatment response Breast cancer classification and prognostication through diverse systems along with recent emerging findings in this respect; the dawn of new perspectives in the clinical applications.Genomancy: predicting tumour response to cancer therapy based on the oracle of genetics.Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature.Ancestry-shift refinement mapping of the C6orf97-ESR1 breast cancer susceptibility locus.HOXB9, a gene overexpressed in breast cancer, promotes tumorigenicity and lung metastasis Genomic distance entrained clustering and regression modelling highlights interacting genomic regions contributing to proliferation in breast cancer Epigenetic repression of the estrogen-regulated Homeobox B13 gene in breast cancer.Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer Positive cross-talk between estrogen receptor and NF-kappaB in breast cancer.Clinical significance of the nuclear receptor co-regulator DC-SCRIPT in breast cancer: an independent retrospective validation study.Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction.Early developments in gene-expression profiling of breast tumors: potential for increasing black-white patient disparities in breast cancer outcomes?A role for estrogen receptor phosphorylation in the resistance to tamoxifen.Analysis of the Hox epigenetic code.HOXB7-S3 inhibits the proliferation and invasion of MCF-7 human breast cancer cells.Prediction and prognosis: impact of gene expression profiling in personalized treatment of breast cancer patients Urinary Nucleic Acid TSPAN13-to-S100A9 Ratio as a Diagnostic Marker in Prostate Cancer.The HOXB13 p.Gly84Glu mutation is not associated with the risk of breast cancer Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance.Re-evaluating early breast neoplasia.HOXB13:IL17BR and molecular grade index and risk of breast cancer death among patients with lymph node-negative invasive disease.A role for biomarkers in the screening and diagnosis of breast cancer in younger women.Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance.Recurrent HOXB13 mutations in the Dutch population do not associate with increased breast cancer risk.Gene expression profiling: changing face of breast cancer classification and management.Current molecular diagnostics of breast cancer and the potential incorporation of microRNA Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients.CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer.Genomic predictors of outcome and treatment response in breast cancer.Preinvasive breast cancer.HOXB13 mediates tamoxifen resistance and invasiveness in human breast cancer by suppressing ERα and inducing IL-6 expression.Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.Engrailed homeobox transcription factors as potential markers and targets in cancer.Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies.Two-gene expression ratio as predictor for breast cancer treated with tamoxifen: evidence from meta-analysis.EN2: a novel prostate cancer biomarker.Molecular tests as prognostic factors in breast cancer.Indications for prognostic gene expression profiling in early breast cancer.Gene-Expression-Based Predictors for Breast Cancer.

P2860

Q27694612-D584F857-066B-4BD4-88B6-8A2792A9386F Q30245184-A9BC212C-16E4-416F-8965-07E8B23F3DA8 Q30440216-E53D9427-8937-4CC9-AD7B-615294CD8A78 Q30854643-C408C681-452B-4716-97EB-3D9E56D5166B Q33641475-DE669595-D36E-4656-A2A7-82E11A0489AB Q33666849-2E43CF19-4D6F-4376-B34A-A0AAA644EE6D Q33687781-D8B2B946-E933-4659-9F1A-CF455C662B04 Q33974237-FCF89665-75D6-44BA-BE99-905E3E305129 Q34173474-438E8435-A3C5-486D-BB3A-3FDF69C258DF Q34374852-5FB4417D-9BBA-47F1-AD1D-7A76F61FC7E6 Q34613612-BB8560E4-0DB5-4B51-B94A-3FDEF9866841 Q35558070-369736EB-9B49-4001-8E1D-725AE3744439 Q35622059-7227C869-B0AC-49B1-B470-5B0536D06F32 Q35684445-55A92556-3A65-4641-9BE7-02DEC647A822 Q35926749-B4BEFEA5-8AC7-4F7B-8A7E-74DDD648E073 Q36089916-A703CD54-954D-4996-B8D6-8334815DDB22 Q36117673-BCEC6AEE-A953-4C33-919B-FBD7448DD7B0 Q36400527-84FBA937-8C1B-4FAA-9B4C-7E8E8753709F Q36438352-81146863-8856-45E1-B6E4-A66592BFB3C6 Q36589865-A3356BB8-3153-4544-BB5B-4F4F1727D76D Q36643056-5510D713-3902-4ACB-BDE1-146D978B6FD8 Q36903062-A0E1AED8-F9FB-4337-B75F-CA7BE2AA76BC Q36950426-F2A3584B-FE12-453E-AC7D-40A82FBCB8D7 Q37000701-96931B19-DAF5-4D88-B6CC-7CEE44E01DA8 Q37101570-94DAF57A-3F37-4BA4-8FBB-40B36DCEE204 Q37169835-2D908A0A-03CF-461A-995B-854B7885B2B0 Q37378012-9CCF6F5D-4508-4E3E-8442-644AED016DE7 Q37444430-307B5923-E454-4374-ACEF-D2200A8DF784 Q37457732-DA5A3C95-B090-4695-8C75-1C750904A4FA Q37523889-9B0093D4-B0E9-4875-A416-A9A7D2A52210 Q37569919-7E9E3DF3-6A7C-4022-AE8E-3E88E716C7D2 Q37668201-F2C9BF19-A409-49A8-8248-D51BEF703ABF Q37871407-FAA279E9-383D-465E-902D-C293760CE937 Q38080336-4F08E227-00F6-4B23-8770-DF90554C7C0E Q38105253-9345C19D-ED73-4CC3-BE28-55FD8530F8A9 Q38165072-122EB113-39F9-4AF9-8D7B-5E0D925529C1 Q38165246-AB76292D-D0C1-45AB-8D9D-2F83C72DEC6C Q38184381-6C50288D-466F-4EAD-A29B-C5A8C30D3C87 Q38451798-53CBDA04-1720-46F9-9D63-92B250E1EDC6 Q38555220-A7F10E6E-EDF0-419C-8AD1-489E4E1583F8

P2860

HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study.

http://www.wikidata.org/entity/Q33274430

description

2007 nî lūn-bûn

@nan

2007 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

HOXB13-to-IL17BR expression ra ...... cancer: a retrospective study.

@ast

HOXB13-to-IL17BR expression ra ...... cancer: a retrospective study.

@en

type

label

HOXB13-to-IL17BR expression ra ...... cancer: a retrospective study.

@ast

HOXB13-to-IL17BR expression ra ...... cancer: a retrospective study.

@en

prefLabel

HOXB13-to-IL17BR expression ra ...... cancer: a retrospective study.

@ast

HOXB13-to-IL17BR expression ra ...... cancer: a retrospective study.

@en

P1433

Q33274430-F6332B21-F3E7-4286-80F3-8C029D5BFD8F

P1476

Q33274430-57998764-1C4D-4871-ADDA-2836DF804DF9

P2093

Q33274430-0861FE87-4919-4B9D-81C1-A2AED1474CA6

Q33274430-3CDF3C60-E272-4A27-A1EA-12A43757E593

Q33274430-3E7C22F5-C937-4351-8637-592F095545C9

Q33274430-42834955-92B3-414B-A359-CFA1B05E8C9F

Q33274430-4399B742-4B31-40ED-A032-34CF5A375503

Q33274430-7B585A59-737C-41F4-AFA2-935FBC652493

Q33274430-7FE89FD2-8533-44EC-9B6B-9D553F9CCDCF

Q33274430-C4C2D1FD-9799-4A41-9FF3-D5FBC859447A

Q33274430-F307502B-998C-49FC-98B3-847F02FCAE27

P304

Q33274430-7CAD31AA-DC1B-4749-A232-84A662BBD346

P31

Q33274430-4FD424D8-6D47-4467-83C8-00A855804597

P356

Q33274430-50938BAD-8A2E-4038-A261-3BC67E3D0C8B

P407

Q33274430-DEAAF952-5EF5-465B-BD53-539FE534AC9A

P433

Q33274430-A2CEDFB4-5089-4265-8BA8-02E54B4C2EA0

P478

Q33274430-BE249113-44AF-449A-9B71-8DE7E13AE177

P577

Q33274430-4541378E-6268-46C4-8A50-143055272283

P5875

Q33274430-D5FC2288-87C2-4B44-A596-47EADC7BC33F

P698

Q33274430-19C7AF11-6F61-47CF-88DA-A85D3EF5F7D5

P356

JCO.2006.07.3676

P1433

Journal of Clinical Oncology

P1476

HOXB13-to-IL17BR expression ra ...... cancer: a retrospective study.

@en

P2093

Anieta M Sieuwerts

http://www.w3.org/2001/XMLSchema#string

Els M J J Berns

http://www.w3.org/2001/XMLSchema#string

Iris L van Staveren

http://www.w3.org/2001/XMLSchema#string

Jan G M Klijn

http://www.w3.org/2001/XMLSchema#string

John A Foekens

http://www.w3.org/2001/XMLSchema#string

Kirsten Ritstier

http://www.w3.org/2001/XMLSchema#string

Marion E Meijer-van Gelder

http://www.w3.org/2001/XMLSchema#string

Maurice P H M Jansen

http://www.w3.org/2001/XMLSchema#string

Maxime P Look

http://www.w3.org/2001/XMLSchema#string

P304

662-668

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2006.07.3676

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2007-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6497894

http://www.w3.org/2001/XMLSchema#string

P698

17308270

http://www.w3.org/2001/XMLSchema#string